Mon – Sat, 9:00 AM – 6:00 PMSafdarjung Enclave, New Delhi+91 11 4000 0000
Book an appointment

NAD+ Therapy

NAD+ therapy is the administration of nicotinamide adenine dinucleotide, or precursors such as NR and NMN, to raise NAD+ levels, which fall with age. Oral precursors consistently raise NAD+ markers and are generally well tolerated, but a 2026 systematic review found no outcome trials of intravenous NAD+ for anti-ageing or wellness.

Every treatment starts with a proper assessment. A clinician reviews your case before anything is recommended.

What it is & how it works

NAD+ is a coenzyme used in energy metabolism and as a signalling molecule for enzymes such as sirtuins; its levels decline with age, and restoring them improves several health measures in animal studies. In people, the evidence is narrower. A 2026 systematic review of 33 human intervention studies found that oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) reliably raise NAD-related markers and are generally well tolerated over weeks to months, but effects on functional, metabolic and vascular outcomes were mixed and often null. It found no eligible outcome trials of intravenous or intramuscular NAD+ itself.

How it's done

After a consultation and baseline blood tests, NAD+ is given either as a slow intravenous infusion (often several hours) or by subcutaneous injection, or an oral precursor may be discussed instead. Infusion rate is kept slow and adjusted to comfort under clinical monitoring. Any course is short and reviewed against how you feel and your markers, rather than continued indefinitely.

Why Unfold Longevity

NAD+ is offered here as an area of active research, not as a proven anti-ageing treatment. You are told before starting that intravenous NAD+ has no outcome trials for ageing or wellness, that oral precursors are a lower-intensity alternative, and what will be measured to decide whether to continue.

Evidence & safety

Human evidence for NAD+ therapy is still developing. Oral NR and NMN have been generally well tolerated in trials of weeks to months; intravenous NAD+ has mainly pharmacokinetic data from small pilot studies. NAD+ therapy is not approved as a treatment for any disease, is not a substitute for managing diabetes, heart disease or other conditions, and no anti-ageing or energy outcome is promised.

Related questions

Is NAD+ therapy proven to slow ageing?

No. NAD+ levels fall with age and raising them helps several measures in animal studies, but human trials have not shown that NAD+ or its precursors slow ageing. A 2026 systematic review found oral NR and NMN raise NAD+ markers with mixed effects on health outcomes, and no outcome trials of intravenous NAD+ for anti-ageing or wellness.

What is the difference between NAD+ IV and NMN or NR supplements?

IV therapy infuses NAD+ itself into a vein over several hours; NMN and NR are oral precursors the body converts into NAD+. Oral precursors have more randomized-trial data and consistently raise NAD+ markers. A pilot study of a 6-hour NAD+ infusion found plasma NAD+ did not rise for the first two hours, suggesting infused NAD+ is rapidly cleared or used.

How many NAD+ sessions are needed?

There is no evidence-based standard number of sessions, because no outcome trials have tested intravenous NAD+ for ageing or wellness. If NAD+ is used, the physician proposes a short, defined course after assessment and reviews it against symptoms and blood markers before any further sessions are considered.

Is NAD+ therapy safe?

Oral NR and NMN have been generally well tolerated in trials lasting weeks to months. Intravenous NAD+ has far less safety data, mostly from small pilot studies, so infusions are run slowly under clinical monitoring and stopped or slowed if you feel unwell. Long-term safety of repeated infusions has not been established.

Who should not have NAD+ therapy?

It is not offered without an assessment. People who are pregnant or breastfeeding, those with active cancer or under cancer treatment, and anyone with significant liver or kidney disease should not start NAD+ therapy without their treating specialist's input, because safety data in these groups are lacking. Your full medical history and medicines are reviewed first.

Care is individualized and outcomes vary between patients.


More in Hormonal & nutrient